X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DR. REDDYS LAB - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DR. REDDYS LAB SANOFI INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 34.5 30.2 114.0% View Chart
P/BV x 6.6 3.0 221.6% View Chart
Dividend Yield % 1.4 0.9 150.7%  

Financials

 SANOFI INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
DR. REDDYS LAB
Mar-17
SANOFI INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs4,5603,397 134.2%   
Low Rs4,4002,560 171.9%   
Sales per share (Unadj.) Rs1,028.5856.5 120.1%  
Earnings per share (Unadj.) Rs129.078.0 165.4%  
Cash flow per share (Unadj.) Rs186.0139.9 132.9%  
Dividends per share (Unadj.) Rs68.0020.00 340.0%  
Dividend yield (eoy) %1.50.7 226.0%  
Book value per share (Unadj.) Rs753.6739.8 101.9%  
Shares outstanding (eoy) m23.03165.74 13.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.43.5 125.3%   
Avg P/E ratio x34.738.2 90.9%  
P/CF ratio (eoy) x24.121.3 113.2%  
Price / Book Value ratio x5.94.0 147.7%  
Dividend payout %52.725.7 205.5%   
Avg Mkt Cap Rs m103,174493,632 20.9%   
No. of employees `0003.622.7 16.0%   
Total wages/salary Rs m3,59231,068 11.6%   
Avg. sales/employee Rs Th6,537.76,259.0 104.5%   
Avg. wages/employee Rs Th991.41,369.8 72.4%   
Avg. net profit/employee Rs Th819.8569.7 143.9%   
INCOME DATA
Net Sales Rs m23,686141,961 16.7%  
Other income Rs m7081,715 41.3%   
Total revenues Rs m24,394143,676 17.0%   
Gross profit Rs m5,28124,722 21.4%  
Depreciation Rs m1,31310,266 12.8%   
Interest Rs m15634 2.4%   
Profit before tax Rs m4,66115,537 30.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6912,965 57.0%   
Profit after tax Rs m2,97012,921 23.0%  
Gross profit margin %22.317.4 128.0%  
Effective tax rate %36.319.1 190.1%   
Net profit margin %12.59.1 137.8%  
BALANCE SHEET DATA
Current assets Rs m15,67396,837 16.2%   
Current liabilities Rs m6,67884,199 7.9%   
Net working cap to sales %38.08.9 426.6%  
Current ratio x2.31.2 204.1%  
Inventory Days Days7673 103.6%  
Debtors Days Days2298 22.8%  
Net fixed assets Rs m8,098102,552 7.9%   
Share capital Rs m230829 27.8%   
"Free" reserves Rs m17,088121,792 14.0%   
Net worth Rs m17,356122,621 14.2%   
Long term debt Rs m05,449 0.0%   
Total assets Rs m25,400218,165 11.6%  
Interest coverage x311.725.5 1,222.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.7 143.3%   
Return on assets %11.86.2 189.1%  
Return on equity %17.110.5 162.4%  
Return on capital %26.912.9 208.9%  
Exports to sales %24.554.6 44.9%   
Imports to sales %28.09.4 299.2%   
Exports (fob) Rs m5,80177,520 7.5%   
Imports (cif) Rs m6,62713,274 49.9%   
Fx inflow Rs m7,14581,670 8.7%   
Fx outflow Rs m6,84626,355 26.0%   
Net fx Rs m29955,315 0.5%   
CASH FLOW
From Operations Rs m3,22621,444 15.0%  
From Investments Rs m-1,555-18,404 8.4%  
From Financial Activity Rs m-1,818-3,692 49.2%  
Net Cashflow Rs m-147-1,144 12.8%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 5.4 266.7%  
FIIs % 14.6 35.3 41.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.5 15.3 68.6%  
Shareholders   15,184 75,885 20.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Down; Tata Steel Top Loser(09:30 am)

Asian stocks rose in morning trade on Monday, after the US's S&P 500 extended its winning streak on Friday to six days. Markets in the Greater China region remain closed for the Lunar New Year holiday.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 19, 2018 10:07 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS